Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of a fixed dose of SR58611A (350mg q12) compared to placebo in
patients with GeneralizedAnxiety Disorder (GAD) using escitalopram (10 mg qd) as positive
control. To evaluate the tolerability and safety of SR58611A in patients with GAD.